The civic record
Read. Follow. Verify.Senate Hearing on Medicare Prescription Drug Prices
Record date · January 1, 2024
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Does
This document is a transcript of a March 16, 2022, Senate Finance Committee hearing focused on rising prescription drug costs within the program. The committee heard testimony from academic, policy, and advocacy experts regarding the economic and health impacts of drug pricing.
The hearing serves as a formal record of legislative inquiry into potential policy changes that could alter how negotiates or regulates drug prices, directly impacting costs for seniors and federal healthcare spending.
Who It Affects
Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.
Medicare beneficiaries
Any changes to drug pricing policy discussed in this hearing could impact the out-of-pocket costs for seniors enrolled in Medicare.
Pharmaceutical companies
Policy changes regarding drug pricing regulation or negotiation could alter the revenue models and pricing strategies for drug manufacturers.
Healthcare providers
Changes in drug pricing and Medicare reimbursement structures affect the operational environment for hospitals and pharmacies.
Key Facts
- The hearing took place on March 16, 2022, in the Dirksen Senate Office Building.
- The primary subject was the inflation of prescription drug prices and the need for cost reduction in Medicare.
- Four expert witnesses provided testimony on the intersection of drug pricing, innovation, and patient access.
- The committee received written communications and statements from over 30 external organizations, including AARP, the American Hospital Association, and the National Taxpayers Union.
Show all 5 facts
- The hearing was held to gather information for potential legislative action regarding Medicare drug pricing policy.
Frequently Asked Questions
What was the purpose of this hearing?
Who testified at the hearing?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceFull breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Broad Stakeholder Engagement
The hearing record includes formal communications from a wide spectrum of organizations, ranging from patient advocacy groups like the National Multiple Sclerosis Society to industry groups like the Association for Accessible Medicines, indicating high-level interest in the policy outcome.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance75How much this matters to a regular citizen
- Controversy60Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz20Current news / social attention level
Publisher tools